BIOREPOSITORY AND TISSUE RESEARCH FACILITY ? PROJECT SUMMARY/ABSTRACT The Biorepository and Tissue Research Facility (BTRF) makes human biospecimens available for basic, translational, and clinical research. It is the major conduit through which human tissue specimens are transferred from the Pathology, Surgery, and other clinical departments to research labs at the University of Virginia (UVA), and is the major processor of human biofluids (tissue, blood, urine) in support of clinical trials at UVA. In addition, this facility provides standard histology services and complex histology-based analytic techniques for animal models of cancer as well as human tissues, including tissue microarray construction, laser microdissection, immunohistochemistry, RNA in situ hybridization and digital slide scanning with automated image analysis. Expert histopathology support from Board-certified Anatomic Pathologists is provided for these activities through this Shared Resource. The biorepository and analytic services are often vertically integrated with each other, including procedures in other core facilities, to allow for ?one-stop shopping? for investigators carrying out translational or clinical cancer research. Examples include next generation sequencing or RNA microarray analysis carried out in the Biomolecular Analysis Facility from nucleic acids extracted from tissue samples by the BTRF; and circulating tumor cell analysis carried out in the Flow Cytometry Core from blood samples processed in the BTRF. In the last CCSG competitive renewal in 2011, the BTRF was awarded a score of ?Outstanding Merit?, since then the BTRF has added new services, new instruments, and new staff with extended operating hours. BTRF services make possible new insights into cancer disease mechanisms by the analysis of tissues and biofluids, assist in the discovery and validation of new clinical cancer biomarkers, and support clinical trials of novel diagnostic tests and therapies for cancer.
| Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655 |
| Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442 |
| Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9 |
| Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425 |
| Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813 |
| Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815 |
| Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429 |
| Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997 |
| Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984 |
| Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117 |
Showing the most recent 10 out of 539 publications
